JANX
NASDAQJanux Therapeutics Inc.
$15.19-0.20 (-1.27%)
News25/Ratings12
News · 26 weeks39+100%
2025-10-262026-04-19
Mix1590d
- Other6(40%)
- SEC Filings3(20%)
- Leadership2(13%)
- Insider2(13%)
- Analyst2(13%)
Latest news
25 items- ANALYSTJanux Therapeutics downgraded by Barclays with a new price targetBarclays downgraded Janux Therapeutics from Overweight to Underweight and set a new price target of $14.00
- PRJanux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014-JANX014 expands Janux's PSMA tumor-activated T cell engager portfolio -JANX007 is the Company's lead prostate cancer program and primary development priority -JANX013, a PSMA-TRACIr CD28 co-stimulatory program, planned to enter the clinic in 2H2026 Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the first patient has been dosed in a Phase 1 clinical trial of JANX014 in patients with metastatic castration-resistant prostate cancer (mCRPC). JANX014 is a double-masked, prostate-specific membrane antigen (PSMA) directed T cell engager (TCE) designed to leverage Janux's tu
- ANALYSTJanux Therapeutics downgraded by UBS with a new price targetUBS downgraded Janux Therapeutics from Buy to Neutral and set a new price target of $15.00
- PRJanux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone PaymentJanux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced the nomination of a development candidate under its collaboration and exclusive worldwide license agreement with Bristol Myers Squibb. The milestone was achieved following the identification of a tumor-activated therapeutic, utilizing Janux's TRACTr platform, targeting an undisclosed solid tumor antigen expressed across several human cancer types, triggering a $35 million milestone payment to Janux. "This milestone underscores the strength of our approach to generating value through both internal innovation and strategic partnersh
- SECSEC Form S-8 filed by Janux Therapeutics Inc.S-8 - Janux Therapeutics, Inc. (0001817713) (Filer)
- SECSEC Form 10-K filed by Janux Therapeutics Inc.10-K - Janux Therapeutics, Inc. (0001817713) (Filer)
- SECJanux Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Janux Therapeutics, Inc. (0001817713) (Filer)
- PRJanux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business HighlightsContinued clinical execution across TRACTr programs JANX007 and JANX008 JANX007 enrolling in Phase 1b Taxane-naïve patient population in metastatic castration-resistant prostate cancer (mCRPC) JANX008 enrolling expansion cohorts in defined tumor settings Initiated Phase 1 study of JANX011 in healthy volunteers Entered collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic for solid tumors Appointment of William Go, M.D., Ph.D., as Chief Medical Officer Strong year-end cash position supporting continued pipeline execution Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharma
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Janux Therapeutics Inc.SCHEDULE 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)
- PRJanux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the first participant has been dosed in a Phase 1 clinical study of JANX011, a CD19-targeted bispecific engineered using the company's proprietary Adaptive Immune Response Modulator (ARM) platform. JANX011 is being developed for autoimmune diseases and is designed to enable deep and durable immune reset through targeted depletion of CD19-expressing B cells in blood and tissue. JANX011 is the first clinical candidate from Janux's proprietary ARM platform, which is designed to deliver sustained target B-cell depletion by harnes
- SECSEC Form SCHEDULE 13G filed by Janux Therapeutics Inc.SCHEDULE 13G - Janux Therapeutics, Inc. (0001817713) (Subject)
- SECSEC Form SCHEDULE 13G filed by Janux Therapeutics Inc.SCHEDULE 13G - Janux Therapeutics, Inc. (0001817713) (Subject)
- INSIDERChief Medical Officer Go William was granted 44,000 shares (SEC Form 4)4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
- INSIDERSEC Form 3 filed by new insider Go William3 - Janux Therapeutics, Inc. (0001817713) (Issuer)
- PRJanux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical OfficerJanux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced that William Go, M.D., Ph.D., has been appointed Chief Medical Officer, effective January 26, 2026. Dr. Go succeeds Zachariah McIver, D.O., Ph.D., who will be leaving the Company to pursue other opportunities. Dr. Go brings more than 20 years of hematology and oncology experience, leading programs from early clinical development through pivotal trials, global regulatory approvals, and first-i
- SECJanux Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Janux Therapeutics, Inc. (0001817713) (Filer)
- PRJanux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid TumorsJanux Therapeutics, Inc. (NASDAQ:JANX) ("Janux"), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb. Under the terms of the agreement, the companies will develop an undisclosed, novel, tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. "This collaboration marks a significant milestone for Janux, val
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Janux Therapeutics Inc.SCHEDULE 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)
- INSIDERPresident and CEO Campbell David Alan sold $110,829 worth of shares (8,072 units at $13.73) and was granted 96,600 shares, increasing direct ownership by 30% to 381,582 units (SEC Form 4)4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
- INSIDERChief Scientific Officer Diraimondo Thomas sold $34,394 worth of shares (2,505 units at $13.73) and was granted 31,400 shares, increasing direct ownership by 23% to 155,825 units (SEC Form 4)4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
- INSIDERChief Medical Officer Mciver Zachariah sold $37,263 worth of shares (2,714 units at $13.73) and was granted 29,000 shares, increasing direct ownership by 101% to 52,286 units (SEC Form 4)4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
- INSIDERChief Technical Officer Winter Charles M. sold $32,966 worth of shares (2,401 units at $13.73) and was granted 28,600 shares, increasing direct ownership by 33% to 106,321 units (SEC Form 4)4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
- INSIDERChief Business Officer Meyer Andrew Hollman sold $25,799 worth of shares (1,879 units at $13.73), decreasing direct ownership by 2% to 83,095 units (SEC Form 4)4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
- INSIDERVice President, Accounting Dobek Maria sold $20,073 worth of shares (1,462 units at $13.73) and was granted 18,935 shares, increasing direct ownership by 104% to 34,308 units (SEC Form 4)4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
- INSIDERChief Corp. & Bus. Dev. Ofcr Doyle Janeen Noel was granted 36,000 shares, increasing direct ownership by 82% to 80,000 units (SEC Form 4)4 - Janux Therapeutics, Inc. (0001817713) (Issuer)